Sun L W, Sun L, Wang P, Kang Y L, Wu Y, Zhu G H, Huang W Y
Department of Nephrology and Rheumatology, Children's Hospital of Shanghai, Children's Hospital of Shanghai Jiao Tong University, Shanghai 200062, China.
Zhonghua Er Ke Za Zhi. 2021 Mar 2;59(3):223-227. doi: 10.3760/cma.j.cn112140-20200824-00822.
To investigate the clinical characteristics, treatment and prognosis of TRPC6 variation induced children with steroid-resistant nephrotic syndrome (SRNS). Clinical data of four patients with nephrotic syndrome carrying TRPC6 variations, who were admitted to the Department of Nephrology and Rheumatology, Children's Hospital of Shanghai from Jan. 2017 to Dec. 2019, was retrospectively analyzed. The literature search was conducted with "nephrotic syndrome" "child" and "TRPC6 variation" as keywords in China National Knowledge Infrastructure (CNKI), Wanfang, Weipu and Pubmed databases until August 2020. One of the four cases was male, and the others were female. Onset age ranged from 4-year-1-month to 12-year-2-month. They presented severe proteinuria, hypoalbuminemia or edema as a first symptom. Four patients had anemia, and two patients had secondary hyperparathyroidism, and one patient had renal atrophy. Renal pathology showed that one case was immune complex associated with glomerulonephritis, and the rest were focal segmental glomerular sclerosis (FSGS). They had been initially treated with corticosteroids for more than four weeks, but they had inadequate responses. They were then treated with corticosteroids combined with immunosuppressants (for example, cyclophosphamide, a calcineurin inhibitor, or mycophenolate mofetil). However, the symptoms did not improve. Additionally, four children progressed to end-stage renal disease within 2 to 6 months.Their whole exon gene testing suggested that the variation types of TRPC6 gene were respectively c.2684G>T, c.523C>T, c.2678G>A, c.2683C>T, and all patients had de novo variations in TRPC6. One article in Chinese and 9 articles in English were found, which made up 27 patients. The data of 31 cases (including this group) were analyzed. There were 18 missense variations, one frameshift variation, one synonymous variation and one splicing variation. The onset age was from 4 months age to 14 years old. Among all patients, 18 cases had massive proteinuria and hypoproteinemia, 6 cases only showed proteinuria. The pathological type of 19 cases were FSGS, 2 cases were IgA nephropathy, 2 cases were minimal change disease, 1 case was collapse glomerulopathy, 1 case was C1q nephropathy, and 1 case was immune complex associated glomerulonephritis. Glucocorticoid therapy was ineffective in 18 cases, and calcineurin inhibitor was ineffective in 11 cases. The prognosis of the disease was poor. Renal failure occurred in 12 cases, and the time to end stage renal disease was from 4 months to 13.8 years. TRPC6 variation can cause SRNS at a young age. FSGS is the primary pathological type of SRNS causing by TRPC6 variation. Glucocorticoid and immunosuppressive therapy are mostly ineffective. The disease progressed rapidly and the prognosis is poor.
探讨瞬时受体电位通道蛋白6(TRPC6)变异所致儿童激素抵抗型肾病综合征(SRNS)的临床特点、治疗及预后。回顾性分析2017年1月至2019年12月上海儿童医学中心肾病风湿科收治的4例携带TRPC6变异的肾病综合征患儿的临床资料。以“肾病综合征”“儿童”“TRPC6变异”为关键词,检索中国知网、万方、维普及Pubmed数据库至2020年8月。4例患儿中1例为男性,其余为女性。起病年龄为4岁1个月至12岁2个月。均以重度蛋白尿、低白蛋白血症或水肿为首发症状。4例有贫血,2例有继发性甲状旁腺功能亢进,1例有肾萎缩。肾病理检查显示,1例为免疫复合物相关性肾小球肾炎,其余为局灶节段性肾小球硬化(FSGS)。初始均接受糖皮质激素治疗4周以上,疗效欠佳。随后采用糖皮质激素联合免疫抑制剂(如环磷酰胺、钙调神经磷酸酶抑制剂或霉酚酸酯)治疗,症状仍未改善。此外,4例患儿在2至6个月内进展至终末期肾病。全外显子基因检测提示,TRPC6基因变异类型分别为c.2684G>T、c.523C>T、c.2678G>A、c.2683C>T,均为新发变异。检索到中文文献1篇、英文文献9篇,共纳入27例患者,分析31例(包括本研究组)患者的数据。其中错义变异18例,移码变异1例,同义变异1例,剪接变异1例。起病年龄为4个月至14岁。所有患者中,18例有大量蛋白尿和低蛋白血症,6例仅表现为蛋白尿。病理类型为FSGS 19例,IgA肾病2例,微小病变肾病2例,塌陷性肾小球病1例,C1q肾病1例,免疫复合物相关性肾小球肾炎1例。18例糖皮质激素治疗无效,11例钙调神经磷酸酶抑制剂治疗无效。疾病预后差。12例发生肾衰竭,进入终末期肾病的时间为4个月至13.8年。TRPC6变异可导致儿童期SRNS。FSGS是TRPC6变异所致SRNS的主要病理类型。糖皮质激素和免疫抑制治疗大多无效。疾病进展迅速,预后差。